Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2021-07-26 Regulatory Filings
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings
2021-07-26 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of an advisory board for Rapid Dose Therapeutics Corp. It details the names and backgrounds of the new advisory board members and includes forward-looking statements typical of corporate announcements. There is no financial data, no mention of a report or filing, no voting results, no regulatory certifications, or other report types. The content is about management/board-related appointments, which fits the category of Board/Management Information (MANG). The document length is 6939 characters, which is sufficient for a full announcement rather than a brief notice. Therefore, the classification is MANG with high confidence.
2021-07-22 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing progress in research collaboration between Rapid Dose Therapeutics and McMaster University on a COVID-19 vaccine delivery technology. It provides updates on pre-clinical testing and scientific development but does not contain any financial data, regulatory filings, or formal report content. There is no indication of financial results, management changes, voting results, or other formal corporate filings. The content is an update on research progress, typical of a corporate news announcement or business update. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-07-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a bi-weekly status report regarding a management cease trade order (MCTO) and updates on delays in filing annual audited financial statements and interim financial statements. It references regulatory guidelines (NP 12-203) and explains reasons for delays, expected filing dates, and compliance status. The document does not contain actual financial statements or detailed financial data but is an update on regulatory compliance and filing status. It is not the financial report itself but a regulatory update related to filings. Therefore, it fits best under Regulatory Filings (RNS).
2021-07-14 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a Master Distribution Agreement between Rapid Dose Therapeutics and Namaste Technologies subsidiary CannMart for distribution of cannabis products. It also announces the launch of a new product, QuickSips biodegradable infused straw. The content focuses on business development, product launch, and partnership details. There are no financial statements, regulatory filings, voting results, or management changes. The document is a corporate announcement about a commercial agreement and product innovation, typical of a Capital/Financing Update or general business update. Given the nature of the announcement about distribution and product launch, the most fitting category is Capital/Financing Update (CAP).
2021-07-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the Ontario Securities Commission (OSC) has granted a management cease trade order (MCTO) on the company's CEO and CFO due to a delay in filing the annual audited financial statements and related documents for the fiscal year ended February 28, 2021. It references the delay in filing the Annual Financial Documents and the company's intention to file them by August 30, 2021. The document also includes a bi-weekly status report on the default and compliance with alternative information guidelines under National Policy 12-203. The document does not contain the actual annual financial statements or management discussion and analysis but is an announcement about the regulatory status and filing delay. It is short (4369 characters) and serves as a regulatory update rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance update rather than an Annual Report (10-K) or Audit Report (AR).
2021-06-30 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.